Clinical Trials · NCT07220629
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- NodThera Limited
- Enrollment
- 82
- Start date
- Oct 2025
- Locations
- 9 sites, United States
- Primary endpoint
- Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs.